TVTX: revenue $169.6M, net income -$34.8M. TVTX revenue +48% on FILSPARI growth; operating income turns positive but net loss widens 173%

Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~1 min read

Key Changes

• high

  Operating income swung to $4.0M from a $12.7M loss, but net loss widened 173% to $34.8M as non-operating/other expenses increased $38.9M YoY (partially offset by $224K tax benefit). The bottom-line deterioration did not come from operations.

  MD&A: Operating Results & Below-the-Line verify on EDGAR →
• high

  In-licensed civorebrutinib (oral BTK inhibitor for rare kidney diseases) from Everest for $112.5M upfront (paid July 2026) plus up to $1.03B in milestones. Adds late-stage asset targeting PMN, FSGS, and MCD.

  MD&A: Civorebrutinib License verify on EDGAR →
• high

  FILSPARI received full FDA approval for FSGS (April 2026), becoming the first approved medicine for this indication. Addressable market: 30,000+ U.S. patients without nephrotic syndrome. Q2 sales $141.1M, up 96% YoY.

  MD&A: FILSPARI FSGS Approval & Sales verify on EDGAR →